Tab Oral lead-in 30 mg cabotegravir + 25 mg rilpivirine once daily during mth 1 (at least 28 days).
Oral dosing for missed cabotegravir inj Mthly IM dosing: 1st dose should be taken 1 mth (±7 days) after the last inj doses of cabotegravir & rilpivirine. May be used to replace up to 2 consecutive mthly inj visits. Every-2-mth IM dosing: 1st dose should be taken 2 mth (±7 days) after the last inj doses of cabotegravir & rilpivirine. May be used to replace one every-2-mth inj visit.
Susp for inj Mthly IM dosing Initiation inj: 600 mg cabotegravir + 900 mg rilpivirine, on the final day of current antiretroviral therapy or oral lead-in therapy. Continuation inj: 400 mg cabotegravir + 600 mg rilpivirine 1 mth after initiation inj & mthly onwards. Patients may be given inj up to 7 days before or after the date of mthly inj schedule.
Every-2-mth IM dosing Initiation inj: 600 mg cabotegravir + 900 mg rilpivirine on the final day of current antiretroviral therapy or oral lead-in therapy & 1 mth later. Patients may be given inj up to 7 days before or after the scheduled dosing date. Continuation inj: 600 mg cabotegravir + 900 mg rilpivirine 2 mth after last initiation inj & every 2 mth onwards. Patients may be given inj up to 7 days before or after the date of the every-2-mth inj schedule.
Switching from mthly to every-2-mth IM dosing Single 600 mg inj 1 mth after the last 400 mg continuation inj & then 600 mg every 2 mth thereafter.
Switching from every-2-mth to mthly IM dosing Single 400 mg inj 2 mth after the last 600 mg continuation inj & then 400 mg mthly thereafter.